Gail Boxer Marcus Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 6 days, 14 hours ago
Gail Boxer Marcus has an estimated net worth of at least $11.9 million*, as of June 10, 2026. They own 17,183 shares of NTRA stock. They have sold 49,311 shares of NTRA stock since 2021, for an estimated $8.1 million.
Gail Boxer Marcus $NTRA SEC Form 4 Insider Trading
Gail Boxer Marcus has filed a total of 37 insider trades in $NTRA since 2021. Their most recent trade was a sale of 4,694 shares, made on Jun 05, 2026. Their largest trade was a sale of 7,582 shares, made on Nov 19, 2024. We estimate that they now own 17,183 shares of $NTRA, worth an estimated $3.8 million.
Insider Trading at $NTRA
There have been a total of 1260 insider trades reported at $NTRA since 2021, with 375,220 shares purchased and 5.1 million shares sold. The most active insider traders in $NTRA stock have been Steven Leonard Chapman, Michael Burkes Brophy, and Solomon Moshkevich. The most recent trade was a sale of 831 shares reported by Matthew Rabinowitz (EXECUTIVE CHAIRMAN), made on Jun 15, 2026.
History of Insider Stock Trades by Gail Boxer Marcus
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
NTRA
|
Sale | 4,694 | Jun 05, 2026 | June 9, 2026, 9:05 p.m. |
NTRA
|
Sale | 3,174 | Jun 05, 2026 | June 9, 2026, 9:05 p.m. |
NTRA
|
Sale | 116 | Jun 05, 2026 | June 9, 2026, 9:05 p.m. |
NTRA
|
Sale | 3,016 | Jun 05, 2026 | June 9, 2026, 9:05 p.m. |
NTRA
|
Sale | 122 | Nov 03, 2025 | Nov. 4, 2025, 10:05 p.m. |
NTRA
|
Sale | 1,183 | Aug 01, 2025 | Aug. 5, 2025, 9:05 p.m. |
NTRA
|
Sale | 1,313 | Aug 01, 2025 | Aug. 5, 2025, 9:05 p.m. |
NTRA
|
Sale | 1,648 | Jul 01, 2025 | July 3, 2025, 9:05 p.m. |
NTRA
|
Sale | 2,651 | Jul 01, 2025 | July 3, 2025, 9:05 p.m. |
NTRA
|
Sale | 600 | Jun 10, 2025 | June 11, 2025, 9:05 p.m. |
NTRA
|
Sale | 3,400 | Jun 10, 2025 | June 11, 2025, 9:05 p.m. |
NTRA
|
Sale | 241 | May 01, 2025 | May 2, 2025, 9:35 p.m. |
NTRA
|
Sale | 341 | May 01, 2025 | May 2, 2025, 9:35 p.m. |
NTRA
|
Sale | 672 | May 01, 2025 | May 2, 2025, 9:35 p.m. |
NTRA
|
Sale | 942 | May 01, 2025 | May 2, 2025, 9:35 p.m. |
NTRA
|
Sale | 1,450 | May 01, 2025 | May 2, 2025, 9:35 p.m. |
NTRA
|
Sale | 31 | May 01, 2025 | May 2, 2025, 9:35 p.m. |
NTRA
|
Sale | 323 | May 01, 2025 | May 2, 2025, 9:35 p.m. |
NTRA
|
Sale | 398 | Apr 01, 2025 | April 3, 2025, 8:35 p.m. |
NTRA
|
Sale | 1,512 | Apr 01, 2025 | April 3, 2025, 8:35 p.m. |
NTRA
|
Sale | 197 | Apr 01, 2025 | April 3, 2025, 8:35 p.m. |
NTRA
|
Sale | 365 | Apr 01, 2025 | April 3, 2025, 8:35 p.m. |
NTRA
|
Sale | 1,528 | Apr 01, 2025 | April 3, 2025, 8:35 p.m. |
NTRA
|
Sale | 381 | Mar 12, 2025 | March 14, 2025, 9:35 p.m. |
NTRA
|
Sale | 1,014 | Mar 12, 2025 | March 14, 2025, 9:35 p.m. |
NTRA
|
Sale | 923 | Mar 12, 2025 | March 14, 2025, 9:35 p.m. |
NTRA
|
Sale | 1,682 | Mar 12, 2025 | March 14, 2025, 9:35 p.m. |
NTRA
|
Sale | 2,100 | Nov 19, 2024 | Nov. 21, 2024, 10:35 p.m. |
NTRA
|
Sale | 7,582 | Nov 19, 2024 | Nov. 21, 2024, 10:35 p.m. |
NTRA
|
Sale | 371 | Nov 14, 2024 | Nov. 15, 2024, 10:05 p.m. |
NTRA
|
Sale | 350 | Nov 14, 2024 | Nov. 15, 2024, 10:05 p.m. |
NTRA
|
Sale | 791 | Nov 14, 2024 | Nov. 15, 2024, 10:05 p.m. |
NTRA
|
Sale | 500 | Nov 14, 2024 | Nov. 15, 2024, 10:05 p.m. |
NTRA
|
Sale | 200 | Nov 14, 2024 | Nov. 15, 2024, 10:05 p.m. |
NTRA
|
Sale | 2,000 | May 30, 2024 | May 31, 2024, 9:05 p.m. |
NTRA
|
Sale | 500 | Dec 08, 2023 | Dec. 12, 2023, 9:35 p.m. |
NTRA
|
Sale | 1,000 | Nov 21, 2023 | Nov. 22, 2023, 9:05 p.m. |
$NTRA Executives and Stock Owners with Insider Trades
-
Steven Leonard Chapman, CEO AND PRESIDENT
-
Michael Burkes Brophy, CHIEF FINANCIAL OFFICER
-
Solomon Moshkevich, PRESIDENT, CLINICALDIAGNOSTICS
-
Matthew Rabinowitz, EXECUTIVE CHAIRMAN
-
Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER
-
John Fesko, PRESIDENT, CHIEF BUS. OFFICER
-
Robert Alan Schueren, CHIEF OPERATING OFFICER
-
Daniel Rabinowitz, CHIEF LEGAL OFFICER
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.